Healthcare

16:53

                            China's 1st, World's 2nd HPV 9-Valent Vaccine Debuts on Global Academic Stage
                        
                            BANGKOK, October 24 (Asia Tech Wire) --The 37th Annual Conference of the International Papillomavirus Society (IPVS) kicked off in Bangkok on October 23, drawing over 1,000 researchers, clinicians, and industry representatives from around the world. Through exhibitions, seminars, and lectures, the conference highlighted the latest advances in papillomavirus research — including China’s independently developed HPV 9-valent vaccine, which stood out as a key highlight.
                        
12:01

                            Hong Kong Stock Market Midday Review: Hang Seng Index rose 1.02%, Hang Seng Tech Index rose 1.48%
                        
                            At the midday close of Hong Kong stocks, the Hang Seng Index rose 1.02%, and the Hang Seng Tech Index rose 1.48%. The Hong Kong Tech ETF (159751) rose 1.71%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.05%. Among sectors, industrial conglomerates and life science tools saw the largest gains. Among individual stocks, WuXi AppTec rose 5.97%, Baidu Group-SW rose 5.6%, Jiangxi Copper Co., Ltd. rose 4.64%, Luoyang Molybdenum Co., Ltd. rose 4.51%, CICC rose 4.5%, and Ganfeng Lithium Co., Ltd. rose 4.15%. Zai Lab fell 4.45%, and Shangao Holdings fell 13.56%. Huaxin Cement rose 11.71%, and Huiju Technology Co., Ltd. rose 9.47%.
                        
11:55

                            UBS raises WuXi AppTec's target price to HK$138.4 and raises its earnings per share forecast for this year
                        
                            UBS published a report stating that WuXi AppTec's revenue in the third quarter increased by 15% year-on-year to 12.1 billion yuan, exceeding the bank's and market forecasts of 11.4 billion yuan and 11.5 billion yuan; net profit increased by 53% year-on-year to 3.5 billion yuan, exceeding the bank's and market forecasts of 3.3 billion yuan and 3.1 billion yuan. As of the end of the third quarter, the backlog of orders for continuing operations increased by 41% year-on-year to 59.9 billion yuan. The company also announced the divestiture of its clinical contract research organization/site management organization business, with an initial transaction price of 2.8 billion yuan. The bank believes that the sale is beneficial to WuXi AppTec as the company can focus on its core contract research, development and manufacturing organization business and its global expansion. The bank raised its earnings per share forecast for the company this year by 23.4%, and its earnings forecast for next year to 2028 by 0.3% to 0.9%; the target price was raised from HK$136.1 to HK$138.4, and the rating was "buy".
                        
20:54

                            Adverum Biotechnologies shares surged 25% in premarket trading after Eli Lilly (LLY.N) announced it would acquire the company.
                        
09:38

                            The Hang Seng Index continued to strengthen, rising by more than 1%. WuXi AppTec (02359.HK) and SMIC (00981.HK) led the gains in constituent stocks. The Hang Seng Tech Index is now up 1.54%.
                        
20:51

                            BGI: Net profit loss in the third quarter was 27.1652 million yuan, down 80.92%
                        
                            BGI announced that its third-quarter revenue was 1.042 billion yuan, a year-on-year increase of 9.19%, while its net profit loss was 27.1652 million yuan, a decrease of 80.92%. For the first three quarters, its revenue was 2.674 billion yuan, a year-on-year decrease of 5.39%, while its net profit loss was 21.387 million yuan, a decrease of 82.78%.
                        
22:03

                            Chairman of the Novo Nordisk (NVO.N) Foundation: We cannot disclose the specific progress of the price reduction negotiations, but we can confirm that the negotiations are likely to lead to lower drug prices in the United States.
                        
22:02

                            Chairman of the Novo Nordisk (NVO.N) Foundation: Negotiations with the Trump administration are ongoing regarding their demands for U.S. prices.
                        
22:02

                            Chairman of the Novo Nordisk (NVO.N) Foundation: I think at least some of the new board members have more direct experience running a pharmaceutical company.
                        
22:01

                            Chairman of the Novo Nordisk (NVO.N) Foundation: Laying off so many employees will cause huge damage.
                        
22:01

                            The Chairman of the Novo Nordisk (NVO.N) Foundation: I believe that the new board members have direct experience in running a pharmaceutical company and will be good training partners for the management.
                        
22:00

                            Chairman of the Novo Nordisk (NVO.N) Foundation: Large-scale staff expansion is a huge failure.
                        
22:00

                            Chairman of the Novo Nordisk (NVO.N) Foundation: The Foundation believes that management is too slow to recognize fundamental changes in the market.
                        
21:16

                            Chairman of the Novo Nordisk (NVO.N) Foundation: We hope that the new board will support Novo Nordisk management in making decisions more quickly.
                        
21:15

                            Chairman of the Novo Nordisk (NVO.N) Foundation: There is no overall disagreement on Novo Nordisk's overall corporate strategy, grand vision and implementation plan.
                        
1761728014
129312
3
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Trends
AI AI Tesla Nvidia Apple Alibaba Xiaomi Tencent Huawei bitcoin
Weekly Highlights